Data from the phase III COMBI-d study showed a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar and Mekinist compared to Tafinlar alone.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
